AETHLON MEDICAL INC

AEMD is the ticker symbol for Aethlon Medical, Inc., a healthcare company focused on developing therapeutic and diagnostic technologies. The stock trades on the Nasdaq Capital Market. AEMD represents ownership shares in the company, giving investors a stake in its operations and future prospects. As a small-cap stock, AEMD often experiences volatility and is followed by investors interested in medical technology and biotech innovations.

Recent performance of AEMD stock can be found in the price chart and performance metrics displayed on this page. The stock's movement may reflect company-specific news, broader market trends, or sector developments. For the latest price changes and percentage gains or losses over various periods, refer to the real-time data provided above.

Evaluating AEMD's valuation involves examining metrics such as price-to-sales, price-to-book, and enterprise value, especially since the company may not have consistent earnings. Investors often compare these ratios to industry peers and consider the company's growth potential, cash burn rate, and pipeline progress. For current valuation metrics, check the financial summary on this page.

AEMD stock may be traded in pre-market and after-hours sessions through certain brokers, though liquidity is typically lower and spreads can be wider. These extended hours allow investors to react to news released outside regular trading. However, not all brokers offer this service, and trading outside regular hours carries additional risks. Check with your brokerage for availability and specific session times.

Earnings information for AEMD, including quarterly reports and annual filings, is available on the SEC's EDGAR database and the company's investor relations website. These reports detail revenue, net income, and other financial results. Additionally, financial news platforms and this stock page may provide earnings dates and summaries. Always refer to official filings for the most accurate and comprehensive data.

Investing in AEMD carries risks such as clinical trial failures, regulatory hurdles, and the need for additional capital, which can dilute shareholders. As a small-cap biotech, the stock may be volatile and sensitive to news. Competitive pressures and reliance on key personnel are also factors. Investors should review the risk factors disclosed in AEMD's SEC filings for a complete picture.